IOMEPROL - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for iomeprol and what is the scope of freedom to operate?
Iomeprol
is the generic ingredient in one branded drug marketed by Bracco and is included in two NDAs. Additional information is available in the individual branded drug profile pages.One supplier is listed for this compound.
Summary for IOMEPROL
| US Patents: | 0 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 2 |
| Drug Master File Entries: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Clinical Trials: | 3 |
| Patent Applications: | 2,896 |
| DailyMed Link: | IOMEPROL at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for IOMEPROL
Generic Entry Dates for IOMEPROL*:
Constraining patent/regulatory exclusivity:
NEW CHEMICAL ENTITY Dosage:
SOLUTION;INTRA-ARTERIAL |
Generic Entry Dates for IOMEPROL*:
Constraining patent/regulatory exclusivity:
NEW CHEMICAL ENTITY Dosage:
SOLUTION;INTRAVENOUS |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for IOMEPROL
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Philippe Gauthier | N/A |
| Guerbet | Phase 4 |
| Deutsches Herzzentrum Muenchen | Phase 4 |
Pharmacology for IOMEPROL
| Drug Class | Radiographic Contrast Agent |
| Mechanism of Action | X-Ray Contrast Activity |
Anatomical Therapeutic Chemical (ATC) Classes for IOMEPROL
US Patents and Regulatory Information for IOMEPROL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bracco | IOMERVU | iomeprol | SOLUTION;INTRA-ARTERIAL | 216016-008 | Nov 27, 2024 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Bracco | IOMERVU | iomeprol | SOLUTION;INTRA-ARTERIAL | 216016-012 | Nov 27, 2024 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Bracco | IOMERVU | iomeprol | SOLUTION;INTRAVENOUS | 216017-003 | Nov 27, 2024 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Bracco | IOMERVU | iomeprol | SOLUTION;INTRAVENOUS | 216017-002 | Nov 27, 2024 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Bracco | IOMERVU | iomeprol | SOLUTION;INTRA-ARTERIAL | 216016-006 | Nov 27, 2024 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Bracco | IOMERVU | iomeprol | SOLUTION;INTRA-ARTERIAL | 216016-001 | Nov 27, 2024 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Bracco | IOMERVU | iomeprol | SOLUTION;INTRA-ARTERIAL | 216016-009 | Nov 27, 2024 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch